Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.

Frontiers in Cellular and Infection Microbiology
Rahul ShuklaNavin Khanna

Abstract

In 2019, the United States Food and Drug Administration accorded restricted approval to Sanofi Pasteur's Dengvaxia, a live attenuated vaccine (LAV) for dengue fever, a mosquito-borne viral disease, caused by four antigenically distinct dengue virus serotypes (DENV 1-4). The reason for this limited approval is the concern that this vaccine sensitized some of the dengue-naïve recipients to severe dengue fever. Recent knowledge about the nature of the immune response elicited by DENV viruses suggests that all LAVs have inherent capacity to predominantly elicit antibodies (Abs) against the pre-membrane (prM) and fusion loop epitope (FLE) of DENV. These antibodies are generally cross-reactive among DENV serotypes carrying a higher risk of promoting Antibody-Dependent Enhancement (ADE). ADE is a phenomenon in which suboptimal neutralizing or non-neutralizing cross-reactive antibodies bind to virus and facilitate Fcγ receptor mediated enhanced entry into host cells, followed by its replication, and thus increasing the cellular viral load. On the other hand, antibody responses directed against the host-cell receptor binding domain of DENV envelope domain-III (EDIII), exhibit a higher degree of type-specificity with lower potential of A...Continue Reading

References

Jul 1, 1977·The Journal of Experimental Medicine·S B Halstead, E J O'Rourke
Jul 26, 2002·The American Journal of Tropical Medicine and Hygiene·Arunee SabchareonNatth Bhamarapravati
May 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Yorgo ModisStephen C Harrison
Dec 31, 2003·Advances in Virus Research·Rebeca Rico-Hesse
Jan 27, 2004·The American Journal of Tropical Medicine and Hygiene·Robert EdelmanWellington Sun
Aug 25, 2005·Expert Review of Vaccines·Thomas P Monath
May 23, 2007·Proceedings of the National Academy of Sciences of the United States of America·Ana P GoncalvezChing-Juh Lai
Oct 8, 2008·Immunological Reviews·Anuja Mathew, Alan L Rothman
Apr 4, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lauren E YauchSujan Shresta
Jan 12, 2010·PLoS Pathogens·Izabela A Rodenhuis-ZybertJolanda M Smit
May 8, 2010·Science·Wanwisa DejnirattisaiGavin Screaton
Jun 4, 2010·Journal of Virology·Jiraphan JunjhonNopporn Sittisombut
Feb 22, 2011·Expert Review of Vaccines·Robert Edelman
Jul 13, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kuan Rong ChanEng Eong Ooi
Jan 31, 2012·Structure·Joseph J B CockburnFelix A Rey
Feb 14, 2012·Structure·Theodore C Pierson, Richard J Kuhn
Apr 13, 2012·The New England Journal of Medicine·Cameron P SimmonsBridget Wills
Apr 14, 2012·Tropical Medicine and Health·Kazuya I P J Hidari, Takashi Suzuki
Jun 23, 2012·Science Translational Medicine·Ee Ping TeohPaul A MacAry
Apr 13, 2013·Proceedings of the National Academy of Sciences of the United States of America·Daniela WeiskopfAlessandro Sette
May 3, 2013·Journal of Virology·Guntur FibriansahShee-Mei Lok
Feb 15, 2014·Current Opinion in Virology·Yorgo Modis
Nov 5, 2014·The New England Journal of Medicine·Luis VillarUNKNOWN CYD15 Study Group

❮ Previous
Next ❯

Citations

Dec 20, 2020·Journal of Clinical Medicine·Miguel A Martín-AcebesNereida Jiménez de Oya
Mar 30, 2021·Frontiers in Immunology·Andrea LombardiAlessandra Bandera
Apr 29, 2021·Archivum Immunologiae Et Therapiae Experimentalis·Karen ManoutcharianGoar Gevorkian
Oct 12, 2021·International Journal of Immunopathology and Pharmacology·Gabriela Athziri Sánchez-ZunoJosé Francisco Muñoz-Valle

❮ Previous
Next ❯

Software Mentioned

Biorender

Related Concepts

Related Feeds

Antibody-Dependent Enhancement

Antibody-dependent enhancement of viral infection is the entry of virus into host cells mediated by antiviral antibodies interacting with Fc or complement receptors. This has been most extensively observed with the dengue virus. Find the latest research on antibody-dependent enhancement here.